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The long QT syndrome (LQTS) is an inherited cardiac
arrhythmia characterized by a prolonged heart rate–corrected
QT interval (QTc) on the surface electrocardiogram (ECG).
It is associated with syncope and sudden cardiac death from
torsades de pointes, and is estimated to affect 1 per 2000
individuals.1 Fifteen genes have been implicated in familial
LQTS, most of which encode cardiac ion channels or
channel-interacting proteins.2 To date, mutations in the
KCNQ1, KCNH2, and SCN5A genes (causing LQTS 1, 2,
and 3) have been found in about 70% of cases, while
mutations in other genes (LQTS 4–15) are found in only 5%,
indicating that for 25% of cases the genetic cause remains
unknown.1
LQTS 14 and 15 are caused by defects in the calmodulin-
encoding genes CALM1 and CALM2,3,4 respectively. More
recently, Reed and colleagues5 described the ﬁrst case of
an infant with LQTS resulting from a CALM3 mutation.
The similarities in clinical characteristics observed in
LQTS patients with calmodulin gene mutations (very early
onset, bradycardia detectable during fetal life, conductionKEYWORDS Long QT syndrome; Calmodulin; CALM3; Whole exome sequen-
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description of a “calmodulinopathy” phenotype.6
In this study we describe 2 gene-elusive early-onset
LQTS subjects, showing sinus bradycardia in utero and
profound QT prolongation after birth (QTc intervals 4600
ms). Based on this extreme LQTS phenotype and the
negative family history, we expected the causal variants in
these subjects to be de novo and to negatively impact protein
amino acid sequence and function. We carried out a
sequencing study of these subjects and identiﬁed 2 novel
variants in CALM3 potentially responsible for the LQTS.Case report
The 2 subjects were diagnosed at the Hospital for Sick
Children in Toronto with a high probability of LQTS based
on Schwartz scores Z3.5 points.7 Informed consent was
obtained for each subject and family members enrolled
according to the procedures approved by the Hospital for
Sick Children Ethics Review Board. Both subjects are of
European descent.
Subject 1 is female and was diagnosed with fetal
bradycardia at 30 weeks of gestation. Fetal ECG identiﬁed
a sinus bradycardia with a heart rate of 109 beats per minute
(bpm) at 32 weeks. Fetal echocardiogram was normal and
anti-Ro and anti-La antibodies were absent. At 36 weeks, 2:1
atrioventricular block in conduction with a ventricular rate of
50–55 bpm was noted. An echocardiogram at 37 weeks was
suggestive of endocardial ﬁbroelastosis, and a coronary
artery–to–left atrial ﬁstula was also identiﬁed. The rhythm
had reverted to sinus bradycardia with 1:1 conduction, with a
slow heart rate of 85 bpm.
Following delivery by caesarean section, the newborn
showed a saturation of 94% and an ECG demonstrated sinus
rhythm with a very long QT interval (QTc¼ 623 ms) and 2:1
atrioventricular block (Figure 1). At 1 day of age, she
reverted to sinus bradycardia with 1:1 conduction (heart
rate ¼ 92 bpm) and a very long QT interval (QTc ¼ 645 ms)
(Figure 1). The coronary artery–to–left atrial ﬁstula waspen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 The human genome contains 3 distinct CALM genes
(CALM1, CALM2, CALM3) located on different
chromosomes that encode identical ubiquitously
expressed calcium-binding protein
calmodulin (CaM).
 Multiple de novo mutations in the 3 calmodulin
genes have been described in infants with severe
early-onset long QT syndrome (LQTS), all of which
are located within the C-terminal Ca2þ-binding
motifs of the protein.
 An LQTS-speciﬁc “calmodulinopathy” phenotype
associated to calmodulin mutations has been
described with a very early onset of the disease
(average age of onset: 3.7 years), with fetal or
neonatal presentation of the disease described in
50% of cases.
 CaM-encoding genes should be considered for
genetic diagnostic testing of patients with LQTS,
especially in young patients with severe symptoms.
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implanted, and she was treated with propranolol 2.4 mg/
kg/day.
She has remained well, without symptoms or arrhythmia,
for 14 years, with ECGs always demonstrating sinus
bradycardia with an atrial paced rhythm and corrected QT
intervals in the 560–650 ms range (Figure 1). She had 1
pacemaker replacement, which was kept in an epicardial
position owing to the presence of tiny apical ventricular
septal defects. The father and the mother are asymptomatic,
showing normal ECGs without bradycardia and normal
corrected QT intervals (QTc ¼ 380 and 399 ms, respec-
tively); both parents were available for genetic testing.
Subject 2 is female, born by caesarean section for a low
biophysical proﬁle score with intrauterine growth retardation
and fetal bradycardia. An ECG identiﬁed sinus bradycardia
at 83 bpm with a very long QT interval (QTc ¼ 627 ms) at 3
days of age (Figure 1). A VVI pacemaker was implanted and
she was treated with propranolol 2.8 mg/kg/day. She had an
episode of cyanosis while she was in her car seat at the age of
1 month, diagnosed as an episode of gastric reﬂux and
inhalation. She has remained well for the last 15 years with
only adjustments in her beta-blockade medication and pacing
rate. The QTc intervals have remained in the 480–660 ms
range (Figure 1). The parents have normal ECGs without
bradycardia and normal corrected QT intervals; only the
mother was available for genetic testing.Methods and results
In order to increase our chances to discover novel LQTS
mutations, we focused our study on 2 very early-onset LQTSsubjects that shared a similar phenotype of sinus bradycardia
in utero with profound QT prolongation after birth. The 2
subjects were found to be negative on genetic testing of the 5
most frequently implicated genes in LQTS (KCNQ1,
KCNH2, SCN5A, KCNE1, and KCNE2). We thus opted to
use a whole exome sequencing approach in order to identify
the underlying genetic causes for LQTS in these probands.
For this, genomic DNA samples were sequenced on the
HiSeq2000 high-throughput sequencing platform (Illumina,
San Diego, CA)) according to the manufacturer’s protocols.
Brieﬂy, the DNA samples were fragmented and linked to
indexed adapters, then ampliﬁed using Illumina’s “Low
Throughput” protocol. Exome enrichment was performed
using Illumina’s “Truseq exome enrichment” kit and exome-
enriched fragments were sequenced using a paired-end (2 
100 bp) protocol at the Beaulieu-Saucier Université de
Montréal Pharmacogenomics Centre. For subjects 1 and 2,
the percentage of bases with a coverage superior to 20 was
80.7% and 82.7%, respectively.
Overall, our whole exome sequencing identiﬁed 59,541
high-quality single nucleotide variants and in/dels for the 2
subjects. Given the prevalence of LQTS, the fact that LQTS
can independently be caused by many different genes and
that most mutations identiﬁed to date are nonsynonymous
and familial in nature, we opted to focus our analyses
exclusively on novel nonsynonymous variants. To achieve
this we ﬁltered out all previously reported variants from
public SNP databases (dbSNP138, 1000 Genome, HapMap,
and ESP6500), as well as all synonymous variants. Follow-
ing this ﬁltering strategy, we identiﬁed 222 novel variants for
the 2 subjects (98 for subject 1 and 109 for subject 2), well
within the expected range of variants for this type of
screening strategy in unrelated individuals.8,9
While we did not identify any causal variant in the 15
known LQTS genes, we identiﬁed 2 novel heterozygous
mutations, p.Phe142Leu and p.Asp96His, for subjects 1 and
2, respectively, in the novel LQTS candidate gene CALM3
(Supplemental Figure 1, available online). We used the
Sequenom Mass Array platform and Sanger sequencing to
independently conﬁrm that the mutations were present in the
subjects and absent in the available unaffected parents
(Supplemental Figure 1), as well as from 540 European-
derived chromosomes, indicating that p.Phe142Leu in sub-
ject 1 is de novo. The heredity status of the p.Asp96His
mutation could not be determined owing to the unavailability
of paternal DNA. The 2 variants, p.Phe142Leu and p.
Asp96His, were predicted as “probably damaging” and
“deleterious” by the pathogenicity scores in Polyphen2 and
PROVEAN, respectively (data not shown).Discussion
The human genome contains 3 distinct CALM genes
(CALM1, CALM2, CALM3) located on different chromo-
somes that show differences at the level of DNA sequences
but encoding an identical ubiquitously expressed calcium-
binding protein, calmodulin (CaM). All 3 genes are
Figure 1 Electrocardiogram (ECG) recordings of subjects 1 and 2. ECGs of subject 1 A: recorded at birth, showing an extreme QTc interval (623 ms) and a
2:1 atrioventricular block (P waves indicated by black arrows), B: at 1 day of age, showing a sinus bradycardia (heart rate of 92 beats per minute [bpm]) and an
extreme QTc interval prolongation (645 ms), and C: at 12 years, showing an extreme QTc interval prolongation (566 ms) and an atrial paced rhythm. ECGs of
subject 2 recordedD: at 3 days of age, showing a sinus bradycardia (heart rate at 83 bpm) and an extreme QTc interval prolongation (627 ms); and E: at 15 years,
showing ventricular paced rhythm at 90 bpm alternating with sinus conducted beats and a QTc interval that remains long (480 ms).
Heart Rhythm Case Reports, Vol 2, No 3, May 2016252expressed in cardiac myocytes, with transcription expression
levels highest for CALM3.3 CaM serves as a calcium sensor
for Ca2þ-dependent inactivation of L-type voltage-gated
Ca2þ channels (Cav1.2).
3,10
In 2013, 3 de novomutations in CALM1 and CALM2were
described in infants with severe early-onset LQTS. Later
studies have found an additional 8 variants in CALM1 and
CALM2 associated with different arrhythmia syndromes,
including LQTS (5 variants), catecholaminergic polymor-
phic ventricular tachycardia (2 variants), and idiopathic
ventricular ﬁbrillation (1 variant) (Supplementary Table 1,
available online).4,11,12 More recently, a missense de novo
mutation in CALM3, p.Asp130Gly, identical to a previously
reported CALM1 mutation, was described in a patient with
early-onset LQTS.5 The fact that the same mutation found in
2 different calmodulin genes causes LQTS is not surprising,
since these genes encode an identical protein, and thus the
pathophysiological impact of the variant is expected to be the
same. All 8 LQTS-associated amino acid changes identiﬁed
to date in CaM are located within the C-terminal (high-
afﬁnity, slowly dissociating) Ca2þ-binding motifs of the
protein (Figure 2).An LQTS-speciﬁc “calmodulinopathy” phenotype
associated to calmodulin mutations has been described
with a very early onset of the disease (average age of
onset: 3.7 years), with fetal or neonatal presentation of the
disease described in 50% of cases. Sinus bradycardia or a
2:1 atrioventricular block are also very frequent, with 6 of
the 10 LQTS cases (60%) described with calmodulin-
associated variants presenting such conduction abnormal-
ities. In the majority of cases (70%), a ventricular
arrhythmia is described, with ventricular ﬁbrillation
identiﬁed in 50% of cases. In all cases, the QTc interval
is extremely long in comparison with other LQTS
(average QTc: 591 ms [478–690 ms]) (Supplementary
Table 1).
Our 2 patients show several characteristics of an LQTS
phenotype associated with calmodulin, with very early onset
of the disease, conduction abnormalities, and extremely long
QT intervals (650 and 660 ms). Similarly to the LQTS
subject described by Reed et al5 with a CALM3mutation, our
2 subjects have not presented any evidence of ventricular
arrhythmias in the last 14–15 years of follow-up. All 3
patients have had an early pacemaker implantation, avoiding
Figure 2 Schematic model of calmodulin and long QT syndrome (LQTS) mutations. Schematic presentation of the calmodulin amino acid sequence showing
the N-terminal and C-terminal domains, each containing 2 Ca2þ binding motifs (in orange). The locations of all published CALM1 (red), CALM2 (purple) and
CALM3 (*,**, ) LQTS mutations are shown. The CALM3 mutations p.Asp96His and p.Phe142Leu were identiﬁed in this study.
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absence of ventricular arrhythmias either could be linked to
an early implantation of the pacemaker or is a characteristic
of CALM3 mutations.
Similarly to the recently reported p.Asp130Gly mutation
in CALM3, the p.Phe142Leu identiﬁed in subject 1 has
previously been reported in CALM1 for a young patient
suffering from LQTS (Supplemental Table 1). We found this
mutation to be de novo, which agrees with the negative
LQTS family history. Published functional studies of p.
Phe142Leu in CALM1 showed that this variant reduces
calcium binding, and in vitro studies demonstrated that this
variant also impaired Ca2þ-dependent inactivation of L-type
voltage-gated Ca2þ channels, leading to prolongation of
ventricular action potentials.3,10,13 For these reasons, we
strongly believe that this variant is the causal LQTS mutation
in this subject. CaM also interacts with the cardiac sodium
channel (Nav1.5) and the voltage-gated potassium channel
(Kv7.1), but the mutations in CALM associated with LQTS
have not been proven to disrupt these 2 channel
functions.13,14
The p.Asp96His mutation identiﬁed in subject 2 was not
previously reported in calmodulin-associated LQTS; how-
ever, the same highly conserved aspartic acid position was
previously reported to be mutated (p.Asp96Val) in CALM2
for LQTS (Supplemental Table 1). As for the p.Phe142Leu
mutation in subject 1, functional studies of the p.Asp96Val
variant in CALM2 showed reduced calcium binding and
impaired Ca2þ-dependent inactivation of L-type voltage-
gated Ca2þ channels, leading to prolongation of ventricular
action potentials.3,10,13 Since the aspartic acid residue is
located in a critical calcium binding loop of the calmodulin
C-terminal domain, any change at that position will likely
result in impaired calcium binding afﬁnities (Figure 2). In
fact, it has been described that the mutations with the greatest
impact on calcium afﬁnity involve substitutions of the
conserved aspartic acid residues known to be directly
involved in coordinating Ca2þ ions in Ca2þ-binding loops.13While we do not have direct functional evidence supporting
the impact of this mutation on CaM function, the predicted
pathogenicity score of the variant, the fact that this position
has previously been implicated in LQTS, and the fact that the
phenotype of subject 2 matches that of the proposed LQTS
“calmodulinopathy” phenotype lead us to believe that this
variant is most likely causal.
Our identiﬁcation of 2 novel mutations in CALM3 further
validates the previously reported role of CALM3 in LQTS
and supports the concept of an LQTS “calmodulinopathy”
phenotype. It should be noted, however, that the lack of
severe clinical manifestations of disease in our patients, and
in the published CALM3 patient following initial identiﬁca-
tion and treatment, highlights the treatability of the LQTS
“calmodulinopathy” phenotype and thus the importance of
rapid and reliable diagnosis. This and the lack of ventricular
arrhythmia in these patients may also suggest the existence
of a CALM3 LQTS “calmodulinopathy” sub-phenotype. The
increasing number of mutations in CaM further illustrates
that the CaM-encoding genes should be considered for
genetic diagnostic testing of patients with LQTS, especially
in young patients with severe symptoms.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://doi:10.1016/10.1016/j.hrcr.
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